Symptomtext
high temperature of 72.7F out of range for 7 weeks with no adverse event; patients were administered post excursion with no adverse event; Initial information was received on 03-Oct-2023 regarding an unsolicited valid non-serious case received from a pharmacist. This case is linked to cases US-SA-2023SA304864 and 2023SA305537. This case involves a 27 years old male patient who experienced high temperature of 72.7f out of range for 7 weeks and influenza quadrival A-B vaccine [FLUZONE QIV] were administered post excursion with no adverse event. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. On 02-Oct-2023, the patient received a 0.5 ml, once dose of suspect influenza quadrival A-B vaccine (Suspension for injection) (lot: UT8055JA, expiry date: 30-Jun-2024 , strength: standard) via intramuscular route in unknown administration site for Immunisation. On an unknown date, high temperature of 72.7f out of range for 7 weeks with no adverse event (product storage error) (unknown Latency)and patients were administered post excursion with no adverse event (poor quality product administered) (Latency: same day). Action taken: not applicable. At time of reporting, the outcome was Unknown for the events. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive and Regulatory Authority Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.